Zepto launches plasma-based FungiFlex Mold panel
March 2026—Zepto Life Technology has launched the FungiFlex Mold panel.
Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
CAP TODAY
BD launches urine collection system
March 2026—BD launched the BD Vacutainer Urine Complete Cup Kit, a three-tube collection system that expands testing capabilities from a single urine specimen.
FDA clears Copan PhenoMatrix software
March 2026—Copan Group’s PhenoMatrix, an automated image assessment software used with the company’s WASPLab laboratory automation platform, received FDA 510(k) clearance as a class II device.
IDT unveils NGS portfolio
March 2026—Integrated DNA Technologies is releasing a suite of next-generation sequencing products that aim to tackle bottlenecks in library preparation, targeted enrichment, and whole genome analysis.
ARUP creates innovation central laboratory
March 2026—ARUP Laboratories has launched an innovation central laboratory to facilitate collaboration with pharmaceutical, biotechnology, and other industry partners.
Illumina launches software for multiomic analysis
March 2026—Illumina has released Illumina Connected Multiomics, a cloud-based research software platform to analyze and visualize multiomic and multimodal biological data at scale.
Guardant360 CDx approved for use with encorafenib
March 2026—The Food and Drug Administration has approved Guardant Health’s Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with encorafenib (Braftovi, Pfizer) in combination with cetuximab and chemotherapy in accordance with the approved product labeling.
Agilent launches S540MD slide scanner system
March 2026—Agilent Technologies launched the Agilent S540MD slide scanner system, a whole slide imaging digital scanner available for sale in select European markets.
Labcorp expands MRD testing
March 2026—Labcorp has expanded its molecular residual disease portfolio to include Labcorp Plasma Detect ID, a whole exome sequence–guided, personalized panel for patients with stages I–III breast cancer or stages I–IIIA non-small cell lung cancer, and Plasma Detect Genome, a whole genome MRD test for stage III colon cancer.
Henry Schein, CytoChip enter distribution agreement
March 2026—Henry Schein entered into an exclusive distribution agreement with CytoChip for CitoCBC, a 510(k)-cleared, CLIA-waived, cartridge-based CBC system. CitoCBC uses blood collected in a venous draw tube to analyze 16 parameters, including the five-part differential. Test results are available in eight minutes.